<DOC>
	<DOCNO>NCT00194025</DOCNO>
	<brief_summary>The purpose research study analyze effectiveness tolerability medication , valproate ( Depakote Depakote ER ) , individual age 50 year old schizophrenia .</brief_summary>
	<brief_title>Valproate Late Life Schizophrenia</brief_title>
	<detailed_description>It know 30 % individual schizophrenia continue symptom even treat current FDA-approved medication intend treat schizophrenia . Anticonvulsant medication valproate ( Depakote Depakote ER ) know effective related condition bipolar disorder ( manic depressive illness ) , also use physician clinical setting combination antipsychotic medication treat symptom schizophrenia . Currently Depakote Depakote ER approve FDA treat bipolar disorder treat seizure disorder . This study test see Depakote Depakote ER may improve symptom schizophrenia well added antipsychotic medication .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Must diagnosis schizophrenia confirm MINI Must antipsychotic medication Must age 50 year old Must capable provide write informed consent study participation . In situation individual guardian person , guardian subject must provide write consent ; Must live Northeast Ohio area . A primary psychiatric DSM Axis I diagnosis schizophrenia Actively abuse substance ; Medically unstable .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Anticonvulsants</keyword>
	<keyword>Valproic Acid</keyword>
	<keyword>Valproate</keyword>
</DOC>